Joincare Pharmaceutical, based in China, has achieved the primary endpoint in a Phase III trial for its flu candidate TG-1000, in collaboration with Taiwan's TaiGen Bio

GSK has reported favorable outcomes from the Phase III EAGLE-1 clinical trial of gepotidacin, an oral bactericidal triazaacenaphthylene antibiotic, in treating uncompli

Marinus Pharmaceuticals announced that its Phase III RAISE study (NCT04391569) of IV ganaxolone for status epilepticus (SE) didn't meet early stopping criteria. They pl

Barinthus Biotherapeutics (formerly Vaccitech) released topline data from its Phase Ib/II APOLLO trial for HPV treatment, VTP-200. The randomized APOLLO trial (NCT04607

Cerevel Therapeutics released positive Phase III TEMPO-3 trial results for tavapadon in Parkinson's disease. Tavapadon, a D1/D5 receptor partial agonist, showed efficac

US-based biopharmaceutical company Acadia Pharmaceuticals has announced that its Phase III ADVANCE-2 clinical trial evaluating pimavanserin for the treatment of negativ

Enlivex Therapeutics has disclosed promising top-line results regarding safety and efficacy from its Phase II clinical trial evaluating Allocetra, an off-the-shelf cell

Teva Pharmaceuticals has released encouraging results from a Phase III trial assessing Ajovy (fremanezumab) for migraine prevention in Chinese adult patients.

Amyyx Pharmaceuticals has released promising interim results from its Phase II trial of Relyvrio (AMX0035) for Wolfram syndrome, a rare disease.

13-04-2024

NeuroGenesis declares positive data from multiple sclerosis trial

The ADRIATIC phase III trial unveiled promising results indicating AstraZeneca’s Imfinzi (durvalumab) significantly enhanced overall survival (OS) and progression

Viking Therapeutics has reported positive data from its Phase I multiple ascending dose (MAD) clinical trial of VK2735, an oral tablet under investigation for treating

Bristol Myers Squibb (BMS) disclosed positive results from its Phase III KRYSTAL-12 trial of KRAZATI (adagrasib) for treating non-small cell lung cancer (NSCLC) with KR

Moderna has disclosed promising interim findings from the Phase III NextCOVE clinical trial, demonstrating the efficacy of its next-generation COVID-19 vaccine candidat

LENZ Therapeutics disclosed positive results from the Phase III CLARITY study assessing aceclidine formulations, LNZ100 and LNZ101, for presbyopia treatment.

HealthNet Global (HNG) introduces its Tele-ICU program at the inauguration of Apollo Spectra Hospital in Pusa Road, Delhi, marking a significant advancement in critical

Pfizer Inc. has announced positive results from a phase 3 trial of Adcetris (brentuximab vedotin) in combination with lenalidomide and rituximab for relapsed/refractory

CuraTeQ Biologics Private Limited, a subsidiary of Aurobindo Pharma Ltd, announced that their omalizumab biosimilar candidate BP11 met phase 1 trial endpoints compared

OcuTerra Therapeutics reported that its Phase II DREAM trial of nesvategrast (OTT166) eye drops for diabetic retinopathy (DR) didn't meet endpoints. The study aimed to

Bristol Myers Squibb has announced positive findings from the phase 3 CheckMate -9DW trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as first-line therapy

Nuvectis Pharma, Inc., a biopharmaceutical company, shared positive preliminary findings from a phase 1b trial of NXP800 for platinum-resistant ARID1a-mutated ovarian c

Ionis Pharmaceuticals, Inc. has released positive outcomes from a phase 2 trial of ION224, an investigational DGAT2 antisense inhibitor targeting metabolic dysfunction-

GSK plc announced positive interim results from the DREAMM-8 phase III trial, comparing Blenrep (belantamab mafodotin) plus pomalidomide and dexamethasone (PomDex) agai

Roche and Alnylam reported positive results from the phase II KARDIA-2 trial [NCT05103332] of zilebesiran, an investigational RNAi therapy for hypertension, a primary c

Bayer AG and BlueRock Therapeutics LP, an independently operated subsidiary of Bayer AG, have disclosed 18-month data from a phase I clinical trial on bemdaneprocel, an

MAIA Biotechnology has released positive efficacy results from its Phase II THIO-101 trial, examining THIO combined with cemiplimab (Libtayo) for advanced non-small cel

Viking Therapeutics, Inc. (Viking), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder treatments, reported positive outcomes f

GSK plc announced positive outcomes from the pivotal EAGLE-1 phase III trial of gepotidacin, an oral antibiotic targeting urogenital gonorrhea in adults and adolescents

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, shares an R&D update. Positive top-line results from a recent phase 1 trial of MTX110 in di

Bristol Myers Squibb revealed findings from the phase 3 DAYBREAK trial, demonstrating Zeposia's (ozanimod) enduring efficacy and safety in relapsing forms of multiple s

Cynata Therapeutics Limited, a biotech firm specializing in cell therapeutics, completed the initial analysis of wound surface area in the first 16 patients of its phas

Novartis revealed new data affirming the clinical advantages of Zolgensma (onasemnogene abeparvovec), the sole one-time gene therapy for spinal muscular atrophy (SMA).<

Ultimovacs, a biotechnology company in its clinical stages, has unveiled data from the Phase II NIPU trial on the UV1 cancer vaccine, focusing on mesothelioma. This tri

Pfizer's Phase III RENOIR trial reveals top-line data on its respiratory syncytial virus (RSV) vaccine, ABRYSVO, targeting RSV-related lower respiratory tract disease (

GSK plc and ViiV Healthcare, a specialized HIV company majority-owned by GSK with Pfizer and Shionogi as shareholders, announced positive phase I study results for cabo

CASI Pharmaceuticals and BioInvent International unveiled positive initial efficacy findings from their Phase I trial of BI-1206 in relapsed/refractory indolent non-Hod

Sanofi, a French pharmaceutical company, is developing frexalimab under an exclusive license from ImmuNext. Positive Phase II trial results were recently announced for

HMB-001 is assessed as a prophylactic treatment for a bleeding disorder, Glanzmann thrombasthenia. Hemab Therapeutics has unveiled encouraging preliminary data from the

The antibody IBI311 showed favorable safety in Thyroid Eye Disease (TED) patients. Innovent Biologics disclosed positive results from the Phase III RESTORE-1 trial in C

Stress urinary incontinence, marked by urine leakage during activities like exercise or sneezing, is the focus of UroMems' latest trial evaluating its UroActive device.

Symptoms of amyotrophic lateral sclerosis (ALS) include hand and arm motor control loss and limb usage impairment. NeuroSense released additional top-line data from its

The LAURA phase III trial highlights AstraZeneca's Tagrisso (osimertinib) as a promising intervention, demonstrating a statistically significant improvement in progress

Tharimmune, a US biotech firm, has unveiled promising data on TH104, a transmucosal buccal film designed for liver-related and inflammatory conditions. TH104 targets ai

Sanofi and Denali Therapeutics' ALS therapy, SAR443820/DNL788, didn't meet its primary endpoint in the Phase II HIMALAYA trial. The trial aimed to gauge its effect on t

Grifols, a leading producer of plasma-derived medicines, announced positive results from Biotest's phase 3 trial of fibrinogen concentrate (FC), BT524, for acquired fib

Grifols, a global leader in plasma-derived medicines, celebrates Biotest's phase 3 trial success with BT524, a fibrinogen concentrate (FC) for acquired fibrinogen defic

Beacon Therapeutics Holdings Limited, a leading ophthalmic gene therapy company, presented interim results from the phase 2 SKYLINE trial for X-linked retinitis pigment

Chugai Pharmaceutical Co., Ltd. announced that the anti-CD20/CD3 bispecific antibody mosunetuzumab met the primary endpoint of complete response rate (CRR) in a Japanes